Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PVSRIPO + unspecified PD-1 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PVSRIPO | PVS-RIPO|NSC-719277|NSC719277 | PVSRIPO is an oncolytic virus comprising a recombinant poliovirus/rhinovirus chimera, which targets CD155 (Necl5)-expressing tumor cells, and potentially induces enhanced anti-tumor immune response and tumor cell cytotoxicity (PMID: 21984883, PMID: 24939611). | ||
| unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04690699 | Phase Ib/II | PVSRIPO + unspecified PD-1 antibody | LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT04577807 | Phase II | PVSRIPO + unspecified PD-1 antibody PVSRIPO | PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma | Completed | USA | 0 |